Protagonist (PTGX) Starts Study On PTG-300 For Blood Disorder
Zacks Investment Research | Jan 06, 2020 09:59PM ET
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that it has initiated a phase II study to evaluate its novel hepcidin mimetic candidate, PTG-300, in patients with hereditary hemochromatosis, a rare blood disorder. The disease results in accumulation of iron in the body's tissues and organs. It can lead to restrictive cardiomyopathy, diastolic dysfunction, heart failure, cirrhosis, and other effects, including an increased risk of hepatocellular carcinoma.
The study will evaluate PTG-300 in patients over 24 weeks for reduction in serum transferrin saturation (“TSAT”), serum iron levels and phlebotomy requirements. The candidate has shown potential to reduce TSAT level in other ongoing clinical studies. Current treatment options for hereditary hemochromatosis include regular phlebotomy (removal of blood) and hormone replacement therapy, which can be a significant burden to patients. Successful development of PTG-300 may reduce the burden.
The company is also developing PTG-300 in mid-stage studies as a treatment for beta-thalassemia and polycythemia vera. The candidate enjoys Orphan Drug designation and Fast Track status in the United States as a treatment for beta-thalassemia.
Shares of Protagonist have declined 6% in the past year compared with the industry ’s decrease of 2.5%.
The company is a clinical stage biopharmaceutical company, which discovers and develops novel peptide-based drugs using its proprietary technology platform targeting diseases with significant unmet medical needs.
Apart from PTG-300, the company is also developing other therapies. A phase II study is evaluating PTG-200 as a treatment for inflammatory bowel disease, with Crohn's disease as the initial indication, in collaboration with Janssen, a subsidiary of J&J (NYSE:JNJ) . A phase II study is likely to start in the second quarter of 2020 to evaluate PN-943 in patients with ulcerative colitis.
Protagonist Therapeutics, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.